Yayın: Pharmacokinetics of intravenous and intramuscular danofloxacin in red-eared slider turtles (Trachemys scripta elegans).
| dc.contributor.author | Corum, Orhan | |
| dc.contributor.author | Corum, Duygu Durna | |
| dc.contributor.author | Altan, Feray | |
| dc.contributor.author | Er, Ayse | |
| dc.contributor.author | Cetin, Gul | |
| dc.contributor.author | Uney, Kamil | |
| dc.date.accessioned | 2026-01-04T12:25:23Z | |
| dc.date.issued | 2018-11-17 | |
| dc.description.abstract | This study aimed to investigate the pharmacokinetics of danofloxacin in red-eared slider turtle (Trachemys scripta elegans) following a single intravenous (IV) and intramuscular (IM) administrations of 6 mg/kg, using a two-way crossover study with 30-day washout period. Eight clinically healthy red-eared slider turtle weighing 410-600 g (mean 490 g) were used for the study. Danofloxacin concentrations were measured using the reversed-phase high-performance liquid chromatography. The plasma concentration-time data were evaluated by a non-compartmental method. After IV administration, the elimination half-life (t1/2 ʎ z), mean residence time (MRT0-∞), area under the concentration-time curve (AUC0-∞), volume of distribution at steady state and total body clearance in plasma were 24.17 hr, 30.64 hr, 143.31 hr·μg/ml, 1.29 l/kg and 0.04 l/hr/kg, respectively. Following IM administration, t1/2ʎz, MRT0-∞AUC0-∞,peak concentration (Cmax), time to reach Cmax, and bioavailability in plasma were 32.00 hr, 41.15 hr, 198.23 hr·μg/ml, 8.75 μg/ml, 1.5 hr and 139.89%, respectively. Danofloxacin has clinically superior pharmacokinetic properties, including the complete IM absorption, slow elimination and wide volume of distribution in redeared slider turtles. However, further pharmacokinetics/pharmacodynamics studies are necessary for the treatment of diseases caused by susceptible bacteria with known minimum inhibitory concentration values in red-eared slider turtles. | |
| dc.description.abstract | PMID:30853667 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/30853667 | |
| dc.description.uri | http://dx.doi.org/10.1292/jvms.18-0609 | |
| dc.description.uri | https://avesis.deu.edu.tr/publication/details/b53c9189-9aff-4c1d-86de-e7d5beadc9e8/oai | |
| dc.description.uri | https://avesis.deu.edu.tr/publication/details/b3c123e9-49b8-446a-9552-49d767b620cf/oai | |
| dc.description.uri | https://www.jstage.jst.go.jp/article/jvms/81/5/81_18-0609/_article | |
| dc.description.uri | https://hdl.handle.net/11468/7582 | |
| dc.description.uri | https://doi.org/10.1292/jvms.18-0609 | |
| dc.description.uri | https://hdl.handle.net/20.500.12395/38083 | |
| dc.identifier.issn | 1347-7439 | |
| dc.identifier.openaire | pmid_dedup__::b9f15c4a949a1a751eec64422a8cbcf9 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/37036 | |
| dc.identifier.volume | 81 | |
| dc.language.iso | eng | |
| dc.publisher | The Japanese Society of Veterinary Science | |
| dc.relation.ispartof | The Journal of veterinary medical science | |
| dc.rights | OPEN | |
| dc.subject | Pharmacology | |
| dc.subject | Cross-Over Studies | |
| dc.subject | Bioavailability | |
| dc.subject | Red-eared slider turtles | |
| dc.subject | Biological Availability | |
| dc.subject | Danofloxacin | |
| dc.subject | Injections, Intramuscular | |
| dc.subject | Turtles | |
| dc.subject | Anti-Infective Agents | |
| dc.subject | red-eared slider turtles | |
| dc.subject | Injections, Intravenous | |
| dc.subject | danofloxacin | |
| dc.subject | Animals | |
| dc.subject | Pharmacokinetics | |
| dc.subject | bioavailability | |
| dc.subject | pharmacokinetics | |
| dc.subject | Fluoroquinolones | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Pharmacokinetics of intravenous and intramuscular danofloxacin in red-eared slider turtles (Trachemys scripta elegans). | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.api.response | {"authors":[{"fullName":"Corum, Orhan","name":"Orhan","surname":"Corum","rank":1,"pid":null},{"fullName":"Corum, Duygu Durna","name":"Duygu Durna","surname":"Corum","rank":2,"pid":null},{"fullName":"Altan, Feray","name":"Feray","surname":"Altan","rank":3,"pid":null},{"fullName":"Er, Ayse","name":"Ayse","surname":"Er","rank":4,"pid":null},{"fullName":"Cetin, Gul","name":"Gul","surname":"Cetin","rank":5,"pid":null},{"fullName":"Uney, Kamil","name":"Kamil","surname":"Uney","rank":6,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Pharmacology"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cross-Over Studies"},"provenance":null},{"subject":{"scheme":"keyword","value":"Bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"Red-eared slider turtles"},"provenance":null},{"subject":{"scheme":"keyword","value":"Biological Availability"},"provenance":null},{"subject":{"scheme":"keyword","value":"Danofloxacin"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intramuscular"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"keyword","value":"Turtles"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-Infective Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"red-eared slider turtles"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intravenous"},"provenance":null},{"subject":{"scheme":"keyword","value":"danofloxacin"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Fluoroquinolones"},"provenance":null}],"mainTitle":"Pharmacokinetics of intravenous and intramuscular danofloxacin in red-eared slider turtles (Trachemys scripta elegans).","subTitle":null,"descriptions":["This study aimed to investigate the pharmacokinetics of danofloxacin in red-eared slider turtle (Trachemys scripta elegans) following a single intravenous (IV) and intramuscular (IM) administrations of 6 mg/kg, using a two-way crossover study with 30-day washout period. Eight clinically healthy red-eared slider turtle weighing 410-600 g (mean 490 g) were used for the study. Danofloxacin concentrations were measured using the reversed-phase high-performance liquid chromatography. The plasma concentration-time data were evaluated by a non-compartmental method. After IV administration, the elimination half-life (t1/2 ʎ z), mean residence time (MRT0-∞), area under the concentration-time curve (AUC0-∞), volume of distribution at steady state and total body clearance in plasma were 24.17 hr, 30.64 hr, 143.31 hr·μg/ml, 1.29 l/kg and 0.04 l/hr/kg, respectively. Following IM administration, t1/2ʎz, MRT0-∞AUC0-∞,peak concentration (Cmax), time to reach Cmax, and bioavailability in plasma were 32.00 hr, 41.15 hr, 198.23 hr·μg/ml, 8.75 μg/ml, 1.5 hr and 139.89%, respectively. Danofloxacin has clinically superior pharmacokinetic properties, including the complete IM absorption, slow elimination and wide volume of distribution in redeared slider turtles. However, further pharmacokinetics/pharmacodynamics studies are necessary for the treatment of diseases caused by susceptible bacteria with known minimum inhibitory concentration values in red-eared slider turtles.","PMID:30853667"],"publicationDate":"2018-11-17","publisher":"The Japanese Society of Veterinary Science","embargoEndDate":null,"sources":["J Vet Med Sci"],"formats":["application/pdf"],"contributors":["Selcuk University Institutional Repository"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"The Journal of veterinary medical science","issnPrinted":"1347-7439","issnOnline":null,"issnLinking":null,"ep":null,"iss":null,"sp":null,"vol":"81","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"pmid_dedup__::b9f15c4a949a1a751eec64422a8cbcf9","originalIds":["od_______267::d5ec595549f373e6992e74bfe87b7678","30853667","PMC6541859","oai:pubmedcentral.nih.gov:6541859","50|od_______267::d5ec595549f373e6992e74bfe87b7678","50|od______2605::715dfe38c1d8b8c0ee34eeeb5d09f993","b53c9189-9aff-4c1d-86de-e7d5beadc9e8","50|od______2605::e223fc8e8cb41bafaf47b67046277efb","b3c123e9-49b8-446a-9552-49d767b620cf","50|od______3346::ec53e8110adc112a2010fdc8773defa9","oai:acikerisim.dicle.edu.tr:11468/7582","oai:acikerisim.selcuk.edu.tr:20.500.12395/38083","50|od______4883::9d536443f29013710cd003182520a1e1"],"pids":[{"scheme":"pmid","value":"30853667"},{"scheme":"pmc","value":"PMC6541859"},{"scheme":"handle","value":"11468/7582"},{"scheme":"handle","value":"20.500.12395/38083"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":7,"influence":2.8600529e-9,"popularity":4.3246096e-9,"impulse":3,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"pmid","value":"30853667"},{"scheme":"pmc","value":"PMC6541859"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1292/jvms.18-0609"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/30853667"],"publicationDate":"2019-12-02","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1292/jvms.18-0609"}],"type":"Other literature type","urls":["http://dx.doi.org/10.1292/jvms.18-0609"],"publicationDate":"2019-03-11","refereed":"nonPeerReviewed"},{"type":"Conference object","urls":["https://avesis.deu.edu.tr/publication/details/b53c9189-9aff-4c1d-86de-e7d5beadc9e8/oai"],"publicationDate":"2018-11-17","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1292/jvms.18-0609"}],"type":"Article","urls":["https://avesis.deu.edu.tr/publication/details/b3c123e9-49b8-446a-9552-49d767b620cf/oai"],"publicationDate":"2019-05-01","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"11468/7582"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1292/jvms.18-0609"}],"type":"Article","urls":["https://www.jstage.jst.go.jp/article/jvms/81/5/81_18-0609/_article","https://hdl.handle.net/11468/7582"],"publicationDate":"2021-09-14","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"20.500.12395/38083"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1292/jvms.18-0609"}],"type":"Article","urls":["https://doi.org/10.1292/jvms.18-0609","https://hdl.handle.net/20.500.12395/38083"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed"}],"isGreen":null,"isInDiamondJournal":null} | |
| local.import.source | OpenAire |
